{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+B-Cell+Non-Hodgkin%27s+Lymphoma&page=8",
    "query": {
      "condition": "High Grade B-Cell Non-Hodgkin's Lymphoma",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 214,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+B-Cell+Non-Hodgkin%27s+Lymphoma&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+B-Cell+Non-Hodgkin%27s+Lymphoma&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T19:13:42.168Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04358458",
      "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Small Lymphocytic Lymphoma",
        "Mantle Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "High-grade B-cell Lymphoma",
        "Primary Mediastinal Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "GEN3009",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2020-03-13",
      "completion_date": "2023-07-28",
      "has_results": true,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Cleveland, Ohio • Columbus, Ohio + 4 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04358458"
    },
    {
      "nct_id": "NCT05755087",
      "title": "Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
        "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
        "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
        "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Tegavivint",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Lapo Alinari",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2023-03-06",
      "completion_date": "2028-03-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755087"
    },
    {
      "nct_id": "NCT00003335",
      "title": "Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "Up to 54 Years"
      },
      "enrollment_count": 44,
      "start_date": "1998-01",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003335"
    },
    {
      "nct_id": "NCT00509691",
      "title": "Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "cytomegalovirus pp65-specific cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "diagnostic laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "2 Years to 120 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509691"
    },
    {
      "nct_id": "NCT01859819",
      "title": "Treatment for Advanced B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large Cell Lymphoma",
        "Burkitt's Lymphoma",
        "High Grade B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "IT Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "3 Years to 31 Years"
      },
      "enrollment_count": 45,
      "start_date": "2013-01",
      "completion_date": "2021-06",
      "has_results": false,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 5,
      "location_summary": "Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859819"
    },
    {
      "nct_id": "NCT05621096",
      "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "DLBCL - Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Follicular Lymphoma",
        "Mediastinal Large B-cell Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bridging radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Liso-cel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Post-infusion radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-03-21",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05621096"
    },
    {
      "nct_id": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation (PBSCT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "15 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2004-03",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2015-03-26",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244946"
    },
    {
      "nct_id": "NCT05672251",
      "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Grade 3b Follicular Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent Transformed Chronic Lymphocytic Leukemia",
        "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Grade 3b Follicular Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Transformed Chronic Lymphocytic Leukemia",
        "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Loncastuximab Tesirine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mosunetuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2024-01-02",
      "completion_date": "2029-08-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05672251"
    },
    {
      "nct_id": "NCT05464329",
      "title": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Large B-cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Transformed B-Cell Lymphoma",
        "Follicular Lymphoma Grade 3B"
      ],
      "interventions": [
        {
          "name": "Mosunetuzumab",
          "type": "DRUG"
        },
        {
          "name": "DHAX",
          "type": "DRUG"
        },
        {
          "name": "ICE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-01-03",
      "completion_date": "2029-10-16",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05464329"
    },
    {
      "nct_id": "NCT00010283",
      "title": "Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Graft Versus Host Disease",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "beclomethasone dipropionate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "5 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-10-14T19:13:42.168Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00010283"
    }
  ]
}